DRUG-INTERACTIONS WITH WARFARIN

被引：39

作者：

BUCKLEY, NA ^{[1
]}

DAWSON, AH ^{[1
]}

机构：

[1] NEWCASTLE MATER MISERICORDIAE HOSP, HUNTER AREA HLTH SERV, DEPT CLIN PHARMACOL & TOXICOL, WARATAH, NSW 2298, AUSTRALIA

来源：

关键词：

D O I：

10.5694/j.1326-5377.1992.tb137313.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：479 / 483

页数：5

共 26 条

[1] DECREASED CAPACITY TO METABOLIZE DIPHENYLHYDANTOIN IN A PATIENT WITH HYPERSENSITIVITY TO WARFARIN
BOCHNER, F
HOOPER, WD
EADIE, MJ
TYRER, JH
[J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1975, 5 (05): : 462 - 466
[2] CIRAULO DA, 1990, J CLIN PSYCHOPHARM, V10, P213
[3] DUKES MNG, 1988, MEYLERS SIDE EFFECTS, P733
[4] Gilman AG., 1990, J MED CHEM, V8th, DOI DOI 10.1021/acs.jmedchem.8b01308
[5] HANSTEN PD, 1991, DRUG INTERACTIONS
[6] RISK-BENEFIT ASSESSMENT OF ANTICOAGULANT-THERAPY
HARRINGTON, R
ANSELL, J
[J]. DRUG SAFETY, 1991, 6 (01) : 54 - 69
[7] ENHANCED ELIMINATION OF WARFARIN DURING TREATMENT WITH CHOLESTYRAMINE
JAHNCHEN, E
MEINERTZ, T
GILFRICH, HJ
KERSTING, F
GROTH, U
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1978, 5 (05) : 437 - 440
[8] KAHER RHM, 1969, AM J MED SCI, V258, P35
[9] GENETIC-VARIATION IN THE HUMAN HEPATIC CYTOCHROME-P-450 SYSTEM
KALOW, W
[J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 31 (06) : 633 - 641
[10] INBORN-ERRORS OF DRUG-METABOLISM - PHARMACOKINETIC AND CLINICAL IMPLICATIONS
LENNARD, MS
TUCKER, GT
WOODS, HF
[J]. CLINICAL PHARMACOKINETICS, 1990, 19 (04) : 257 - 263